Research Article

Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis

Table 1

Characteristics of the studies included in the meta-analysis.

AuthorYearCountryNo. of patientsEthnicitySex (M/F)Tumor locationFollow-up (months)
Median (range)
Study designTreatmentSurvival outcomePD-L1 (+)
(%)
NOS score

Ahn, S.2019Korea183Asian122/61eCCA27.2RetrospectiveSurgeryOS, DFS31 (16.9)7
Arkenau, H. T.2018UK26Caucasian8/18CCA6.4 (4.1-13.2)ProspectiveTargeted therapy + immunotherapyOS, DFS12 (46.2)8
Dong, Z. T.2020China125Asian58/77iCCA16 (5-63)RetrospectiveSurgeryOS, DFS52 (41.6)7
Gani, F.2016USA54Caucasian17/37iCCANRRetrospectiveSurgeryOS39 (72.2)6
Gou, M. M.2019China30Asian18/12CCATo Sep 2018RetrospectiveImmunotherapyDFS11 (36.6)7
Jing, C. Y.2019China153AsianNRiCCA47.5 (1-88.4)RetrospectiveSurgeryOS43 (28.1)7
Kim, R.2018USA44Caucasian23/21eCCANRRetrospectiveSurgeryOS10 (22.7)6
Kitano, Y.2020Japan177Asian115/62CCA78.7RetrospectiveSurgeryOS54 (30.5)6
Kriegsmann, M.2019Germany170Caucasian109/61CCANRRetrospectiveSurgeryOS19 (11.1)6
Lim, Y. J.2015Korea83Asian61/22eCCA27RetrospectiveSurgeryOS, DFS56 (83)7
Lu, J. C.2019China320Asian19/129iCCATo Oct 2016RetrospectiveSurgeryOS, DFS99 (30.9)7
Ma, K.2017China70Asian38/32eCCATo Mar 2015RetrospectiveSurgeryOS30 (42.9)7
Sangkhamanon, S.2017Thailand46Asian33/13CCANRRetrospectiveSurgeryOS18 (39.1)6
Tamai, K.2014Japan91Asian62/29eCCANRRetrospectiveSurgeryOS77 (84.6)6
Ueno, T.2018Japan117Asian93/24eCCA27 (0-189)RetrospectiveSurgeryOS10 (8.5)7
Walter, D.2017Germany69Caucasian50/19eCCA23 (0-100)RetrospectiveSurgeryOS8 (11.6)7
Yu, F.2019China62Asian41/21eCCANRRetrospectiveSurgeryOS, DFS20 (32.3)6
Zhu, Y.2018China192Asian115/77iCCA24 (0.4-85)RetrospectiveSurgeryOS, DFS34 (17.7)7

CCA: cholangiocarcinoma; eCCA: extrahepatic cholangiocarcinoma; iCCA: intrahepatic cholangiocarcinoma; NR: not reported; OS: overall survival; DFS: disease-free survival; NOS: Newcastle-Ottawa scale. CCA includes iCCA and eCCA.